Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 39fludarabine phosphate 37Azacitidine 33fludarabine 25Whole-Body Irradiation 22Busulfan 22Tacrolimus 21Antilymphocyte Serum 21Mycophenolic Acid 19Filgrastim 18Methotrexate 16Melphalan 15venetoclax 13Peripheral Blood Stem Cell Transplantation 13Granulocyte Colony-Stimulating Factor 13Cytarabine 13thymoglobulin 12Cyclosporine 12Thiotepa 9Cord Blood Stem Cell Transplantation 9Alemtuzumab 8Rituximab 7Radiotherapy 7Methylprednisolone 7Decitabine 7Clofarabine 7Lenalidomide 6Stem Cell Transplantation 5Sirolimus 5Nivolumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Myelodysplastic Syndromes × lirilumab × Clear all
NCT02599649 2020-01-14

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

M.D. Anderson Cancer Center

Phase 2 Terminated
10 enrolled 8 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡